Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 548

1.

A decade with whole exome sequencing in hematology.

Hansen MC, Haferlach T, Nyvold CG.

Br J Haematol. 2019 Oct 10. doi: 10.1111/bjh.16249. [Epub ahead of print] Review.

PMID:
31602633
2.

MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis.

Jawhar M, Schwaab J, Álvarez-Twose I, Shoumariyeh K, Naumann N, Lübke J, Perkins C, Muñoz-González JI, Meggendorfer M, Kennedy V, Metzgeroth G, Fabarius A, Pfeifer D, Sotlar K, Horny HP, von Bubnoff N, Haferlach T, Cross NCP, Hofmann WK, Sperr WR, García-Montero AC, Valent P, Gotlib J, Orfao A, Reiter A.

J Clin Oncol. 2019 Sep 11:JCO1900640. doi: 10.1200/JCO.19.00640. [Epub ahead of print]

PMID:
31509472
3.

Dark-matter matters: Discriminating subtle blood cancers using the darkest DNA.

Parida L, Haferlach C, Rhrissorrakrai K, Utro F, Levovitz C, Kern W, Nadarajah N, Twardziok S, Hutter S, Meggendorfer M, Walter W, Baer C, Haferlach T.

PLoS Comput Biol. 2019 Aug 30;15(8):e1007332. doi: 10.1371/journal.pcbi.1007332. eCollection 2019 Aug.

4.

Molecular characterization of acute myeloid leukemia patients who relapse more than 3 years after diagnosis: an exome sequencing study of 31 patients.

Hartmann L, Haferlach C, Meggendorfer M, Nadarajah N, Kern W, Haferlach T, Stengel A.

Haematologica. 2019 Aug 1. pii: haematol.2019.227702. doi: 10.3324/haematol.2019.227702. [Epub ahead of print]

5.

Differences in treatment and monitoring of chronic myeloid leukemia with regard to age, but not sex: Results from a population-based study.

Lauseker M, Gerlach R, Worseg W, Haferlach T, Tauscher M, Hasford J, Hoffmann VS.

Eur J Haematol. 2019 Oct;103(4):362-369. doi: 10.1111/ejh.13293. Epub 2019 Aug 28.

PMID:
31309640
6.

Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse.

Iaccarino L, Ottone T, Alfonso V, Cicconi L, Divona M, Lavorgna S, Travaglini S, Ferrantini A, Falconi G, Baer C, Usai M, Forghieri F, Venditti A, Del Principe MI, Arcese W, Voso MT, Haferlach T, Lo-Coco F.

Am J Hematol. 2019 Oct;94(10):1091-1097. doi: 10.1002/ajh.25573. Epub 2019 Jul 23.

PMID:
31292998
7.

"Somatic" and "pathogenic" - is the classification strategy applicable in times of large-scale sequencing?

Baer C, Walter W, Hutter S, Twardziok S, Meggendorfer M, Kern W, Haferlach T, Haferlach C.

Haematologica. 2019 Aug;104(8):1515-1520. doi: 10.3324/haematol.2019.218917. Epub 2019 Jul 4. No abstract available.

8.

DNMT3A mutations are over-represented in young adults with NPM1 mutated AML and prompt a distinct co-mutational pattern.

Cappelli LV, Meggendorfer M, Dicker F, Jeromin S, Hutter S, Kern W, Haferlach T, Haferlach C, Höllein A.

Leukemia. 2019 Jun 17. doi: 10.1038/s41375-019-0502-0. [Epub ahead of print] No abstract available.

PMID:
31209279
9.

Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms.

Schischlik F, Jäger R, Rosebrock F, Hug E, Schuster M, Holly R, Fuchs E, Milosevic Feenstra JD, Bogner E, Gisslinger B, Schalling M, Rumi E, Pietra D, Fischer G, Faé I, Vulliard L, Menche J, Haferlach T, Meggendorfer M, Stengel A, Bock C, Cazzola M, Gisslinger H, Kralovics R.

Blood. 2019 Jul 11;134(2):199-210. doi: 10.1182/blood.2019000519. Epub 2019 May 7.

10.

Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions.

Valent P, Orazi A, Savona MR, Patnaik MM, Onida F, van de Loosdrecht AA, Haase D, Haferlach T, Elena C, Pleyer L, Kern W, Pemovska T, Vladimer GI, Schanz J, Keller A, Lübbert M, Lion T, Sotlar K, Reiter A, De Witte T, Pfeilstöcker M, Geissler K, Padron E, Deininger M, Orfao A, Horny HP, Greenberg PL, Arber DA, Malcovati L, Bennett JM.

Haematologica. 2019 Oct;104(10):1935-1949. doi: 10.3324/haematol.2019.222059. Epub 2019 May 2.

11.

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose.

Jilg S, Hauch RT, Kauschinger J, Buschhorn L, Odinius TO, Dill V, Müller-Thomas C, Herold T, Prodinger PM, Schmidt B, Hempel D, Bassermann F, Peschel C, Götze KS, Höckendorf U, Haferlach T, Jost PJ.

Exp Hematol Oncol. 2019 Apr 16;8:9. doi: 10.1186/s40164-019-0133-1. eCollection 2019.

12.

RUNX1 mutations in MDS, s-AML, and de novo AML: differences in accompanying genetic alterations and outcome.

Stengel A, Kern W, Meggendorfer M, Haferlach T, Haferlach C.

Leuk Lymphoma. 2019 May;60(5):1334-1336. doi: 10.1080/10428194.2018.1522439. No abstract available.

PMID:
30997874
13.

Myeloid malignancies with isolated 7q deletion can be further characterized by their accompanying molecular mutations.

Hartmann L, Haferlach C, Meggendorfer M, Kern W, Haferlach T, Stengel A.

Genes Chromosomes Cancer. 2019 Oct;58(10):698-704. doi: 10.1002/gcc.22761. Epub 2019 May 1.

PMID:
30994218
14.

Impact of 9q deletions on the classification of patients with acute myeloid leukemia.

Balk B, Haferlach T, Meggendorfer M, Kern W, Haferlach C, Stengel A.

J Cancer Res Clin Oncol. 2019 Mar 29. doi: 10.1007/s00432-019-02908-0. [Epub ahead of print] No abstract available.

PMID:
30927073
15.

Genomic subtyping and therapeutic targeting of acute erythroleukemia.

Iacobucci I, Wen J, Meggendorfer M, Choi JK, Shi L, Pounds SB, Carmichael CL, Masih KE, Morris SM, Lindsley RC, Janke LJ, Alexander TB, Song G, Qu C, Li Y, Payne-Turner D, Tomizawa D, Kiyokawa N, Valentine M, Valentine V, Basso G, Locatelli F, Enemark EJ, Kham SKY, Yeoh AEJ, Ma X, Zhou X, Sioson E, Rusch M, Ries RE, Stieglitz E, Hunger SP, Wei AH, To LB, Lewis ID, D'Andrea RJ, Kile BT, Brown AL, Scott HS, Hahn CN, Marlton P, Pei D, Cheng C, Loh ML, Ebert BL, Meshinchi S, Haferlach T, Mullighan CG.

Nat Genet. 2019 Apr;51(4):694-704. doi: 10.1038/s41588-019-0375-1. Epub 2019 Mar 29.

PMID:
30926971
16.

Impact of assay procedures on detection of MR4.5 status in chronic myeloid leukemia: Optimization of cDNA synthesis.

Jeromin S, Eder C, Haferlach C, Haferlach T, Kern W.

Int J Lab Hematol. 2019 Oct;41(5):e109-e112. doi: 10.1111/ijlh.13004. Epub 2019 Mar 12. No abstract available.

PMID:
30860652
17.

More than a fusion gene: the RUNX1-RUNX1T1 AML.

Haferlach T, Meggendorfer M.

Blood. 2019 Mar 7;133(10):1006-1007. doi: 10.1182/blood-2019-01-896076. No abstract available.

PMID:
30846508
18.

Comprehensive molecular characterization of myeloid malignancies with 9q deletion.

Hartmann L, Haferlach T, Meggendorfer M, Kern W, Haferlach C, Stengel A.

Leuk Lymphoma. 2019 Oct;60(10):2591-2593. doi: 10.1080/10428194.2019.1585840. Epub 2019 Mar 7. No abstract available.

PMID:
30844315
19.

Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML.

Valent P, Kern W, Hoermann G, Milosevic Feenstra JD, Sotlar K, Pfeilstöcker M, Germing U, Sperr WR, Reiter A, Wolf D, Arock M, Haferlach T, Horny HP.

Int J Mol Sci. 2019 Feb 12;20(3). pii: E789. doi: 10.3390/ijms20030789. Review.

20.

GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations.

Sportoletti P, Celani L, Varasano E, Rossi R, Sorcini D, Rompietti C, Strozzini F, Del Papa B, Guarente V, Spinozzi G, Cecchini D, Bereshchenko O, Haferlach T, Martelli MP, Falzetti F, Falini B.

Leukemia. 2019 Jul;33(7):1827-1832. doi: 10.1038/s41375-019-0399-7. Epub 2019 Feb 12. No abstract available.

21.

Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia.

Awada H, Nagata Y, Goyal A, Asad MF, Patel B, Hirsch CM, Kuzmanovic T, Guan Y, Przychodzen BP, Aly M, Adema V, Shen W, Williams L, Nazha A, Abazeed ME, Sekeres MA, Radivoyevitch T, Haferlach T, Jha BK, Visconte V, Maciejewski JP.

Blood Adv. 2019 Feb 12;3(3):339-349. doi: 10.1182/bloodadvances.2018024216.

22.

Evidence of clonality in cases of hypereosinophilia of undetermined significance.

Pohlkamp C, Vetro C, Dicker F, Meggendorfer M, Kern W, Haferlach C, Haferlach T.

Leuk Lymphoma. 2019 Aug;60(8):2071-2074. doi: 10.1080/10428194.2018.1564825. Epub 2019 Jan 18. No abstract available.

PMID:
30656986
23.

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee.

Leukemia. 2019 Jul;33(7):1747-1758. doi: 10.1038/s41375-018-0351-2. Epub 2019 Jan 11.

24.

KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis.

Jawhar M, Döhner K, Kreil S, Schwaab J, Shoumariyeh K, Meggendorfer M, Span LLF, Fuhrmann S, Naumann N, Horny HP, Sotlar K, Kubuschok B, von Bubnoff N, Spiekermann K, Heuser M, Metzgeroth G, Fabarius A, Klein S, Hofmann WK, Kluin-Nelemans HC, Haferlach T, Döhner H, Cross NCP, Sperr WR, Valent P, Reiter A.

Leukemia. 2019 May;33(5):1124-1134. doi: 10.1038/s41375-018-0346-z. Epub 2019 Jan 11.

25.

IDH1-R132 changes vary according to NPM1 and other mutations status in AML.

Falini B, Spinelli O, Meggendorfer M, Martelli MP, Bigerna B, Ascani S, Stein H, Rambaldi A, Haferlach T.

Leukemia. 2019 Apr;33(4):1043-1047. doi: 10.1038/s41375-018-0299-2. Epub 2019 Jan 8. No abstract available.

26.

Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery.

Simonetti G, Padella A, do Valle IF, Fontana MC, Fonzi E, Bruno S, Baldazzi C, Guadagnuolo V, Manfrini M, Ferrari A, Paolini S, Papayannidis C, Marconi G, Franchini E, Zuffa E, Laginestra MA, Zanotti F, Astolfi A, Iacobucci I, Bernardi S, Sazzini M, Ficarra E, Hernandez JM, Vandenberghe P, Cools J, Bullinger L, Ottaviani E, Testoni N, Cavo M, Haferlach T, Castellani G, Remondini D, Martinelli G.

Cancer. 2019 Mar 1;125(5):712-725. doi: 10.1002/cncr.31837. Epub 2018 Nov 27.

27.

Dreams can come true: the first steps toward a peripheral blood screening test for the early detection of tumors have been taken.

Haferlach C, Haferlach T.

Ann Oncol. 2019 Jan 1;30(1):12-13. doi: 10.1093/annonc/mdy499. No abstract available.

PMID:
30462156
28.

Detailed molecular analysis and evaluation of prognosis in cases with high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.

Stengel A, Kern W, Meggendorfer M, Haferlach T, Haferlach C.

Br J Haematol. 2019 Jun;185(5):951-954. doi: 10.1111/bjh.15653. Epub 2018 Nov 20. No abstract available.

PMID:
30460680
29.

NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse.

Höllein A, Meggendorfer M, Dicker F, Jeromin S, Nadarajah N, Kern W, Haferlach C, Haferlach T.

Blood Adv. 2018 Nov 27;2(22):3118-3125. doi: 10.1182/bloodadvances.2018023432.

30.

Detection and characterization of homozygosity of mutated CALR by copy neutral loss of heterozygosity in myeloproliferative neoplasms among cases with high CALR mutation loads or with progressive disease.

Stengel A, Jeromin S, Haferlach T, Meggendorfer M, Kern W, Haferlach C.

Haematologica. 2019 May;104(5):e187-e190. doi: 10.3324/haematol.2018.202952. Epub 2018 Nov 8. No abstract available.

31.

Comprehensive genetic diagnosis of acute myeloid leukemia by next-generation sequencing.

Mack EKM, Marquardt A, Langer D, Ross P, Ultsch A, Kiehl MG, Mack HID, Haferlach T, Neubauer A, Brendel C.

Haematologica. 2019 Feb;104(2):277-287. doi: 10.3324/haematol.2018.194258. Epub 2018 Sep 6.

32.

ASXL2 regulates hematopoiesis in mice and its deficiency promotes myeloid expansion.

Madan V, Han L, Hattori N, Teoh WW, Mayakonda A, Sun QY, Ding LW, Nordin HBM, Lim SL, Shyamsunder P, Dakle P, Sundaresan J, Doan NB, Sanada M, Sato-Otsubo A, Meggendorfer M, Yang H, Said JW, Ogawa S, Haferlach T, Liang DC, Shih LY, Nakamaki T, Wang QT, Koeffler HP.

Haematologica. 2018 Dec;103(12):1980-1990. doi: 10.3324/haematol.2018.189928. Epub 2018 Aug 9.

33.

Identification of prognostic parameters in CLL with no abnormalities detected by chromosome banding and FISH analyses.

Vetro C, Haferlach T, Jeromin S, Stengel A, Zenger M, Nadarajah N, Baer C, Weissmann S, Kern W, Meggendorfer M, Haferlach C.

Br J Haematol. 2018 Oct;183(1):47-59. doi: 10.1111/bjh.15498. Epub 2018 Jul 18.

PMID:
30022491
34.

Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature.

Kuendgen A, Müller-Thomas C, Lauseker M, Haferlach T, Urbaniak P, Schroeder T, Brings C, Wulfert M, Meggendorfer M, Hildebrandt B, Betz B, Royer-Pokora B, Gattermann N, Haas R, Germing U, Götze KS.

Oncotarget. 2018 Jun 12;9(45):27882-27894. doi: 10.18632/oncotarget.25328. eCollection 2018 Jun 12. Review.

35.

Consequences of mutant TET2 on clonality and subclonal hierarchy.

Hirsch CM, Nazha A, Kneen K, Abazeed ME, Meggendorfer M, Przychodzen BP, Nadarajah N, Adema V, Nagata Y, Goyal A, Awada H, Asad MF, Visconte V, Guan Y, Sekeres MA, Olinski R, Jha BK, LaFramboise T, Radivoyevitch T, Haferlach T, Maciejewski JP.

Leukemia. 2018 Aug;32(8):1751-1761. doi: 10.1038/s41375-018-0150-9. Epub 2018 May 24.

PMID:
29795413
36.

The Molecular Pathology of Myelodysplastic Syndrome.

Haferlach T.

Pathobiology. 2019;86(1):24-29. doi: 10.1159/000488712. Epub 2018 May 23. Review.

PMID:
29791902
37.

Molecular patterns in cytopenia patients with or without evidence of myeloid neoplasm-a comparison of 756 cases.

Baer C, Pohlkamp C, Haferlach C, Kern W, Haferlach T.

Leukemia. 2018 Oct;32(10):2295-2298. doi: 10.1038/s41375-018-0119-8. Epub 2018 Mar 30. No abstract available.

PMID:
29725031
38.

Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile.

Reidel V, Kauschinger J, Hauch RT, Müller-Thomas C, Nadarajah N, Burgkart R, Schmidt B, Hempel D, Jacob A, Slotta-Huspenina J, Höckendorf U, Peschel C, Kern W, Haferlach T, Götze KS, Jilg S, Jost PJ.

Oncotarget. 2018 Apr 3;9(25):17270-17281. doi: 10.18632/oncotarget.24775. eCollection 2018 Apr 3.

39.

The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic/myeloproliferative neoplasms.

Meggendorfer M, Jeromin S, Haferlach C, Kern W, Haferlach T.

Haematologica. 2018 May;103(5):e192-e195. doi: 10.3324/haematol.2017.183160. No abstract available.

40.

Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia.

Itzykson R, Duployez N, Fasan A, Decool G, Marceau-Renaut A, Meggendorfer M, Jourdan E, Petit A, Lapillonne H, Micol JB, Cornillet-Lefebvre P, Ifrah N, Leverger G, Dombret H, Boissel N, Haferlach T, Preudhomme C.

Blood. 2018 Jul 12;132(2):187-196. doi: 10.1182/blood-2018-03-837781. Epub 2018 Apr 24.

PMID:
29692343
41.

Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients.

Höllein A, Jeromin S, Meggendorfer M, Fasan A, Nadarajah N, Kern W, Haferlach C, Haferlach T.

Leukemia. 2018 Oct;32(10):2270-2274. doi: 10.1038/s41375-018-0086-0. Epub 2018 Mar 6. No abstract available.

PMID:
29568097
42.

IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies.

Meggendorfer M, Cappelli LV, Walter W, Haferlach C, Kern W, Falini B, Haferlach T.

Leukemia. 2018 May;32(5):1249-1253. doi: 10.1038/s41375-018-0026-z. Epub 2018 Jan 30. No abstract available.

PMID:
29568090
43.

Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2.

Baer C, Muehlbacher V, Kern W, Haferlach C, Haferlach T.

Haematologica. 2018 Aug;103(8):e348-e350. doi: 10.3324/haematol.2017.187302. Epub 2018 Mar 22. No abstract available.

44.

Detection of recurrent and of novel fusion transcripts in myeloid malignancies by targeted RNA sequencing.

Stengel A, Nadarajah N, Haferlach T, Dicker F, Kern W, Meggendorfer M, Haferlach C.

Leukemia. 2018 May;32(5):1229-1238. doi: 10.1038/s41375-017-0002-z. Epub 2018 Feb 26. No abstract available.

PMID:
29479069
45.

Chromothripsis in acute myeloid leukemia: biological features and impact on survival.

Fontana MC, Marconi G, Feenstra JDM, Fonzi E, Papayannidis C, Ghelli Luserna di Rorá A, Padella A, Solli V, Franchini E, Ottaviani E, Ferrari A, Baldazzi C, Testoni N, Iacobucci I, Soverini S, Haferlach T, Guadagnuolo V, Semerad L, Doubek M, Steurer M, Racil Z, Paolini S, Manfrini M, Cavo M, Simonetti G, Kralovics R, Martinelli G.

Leukemia. 2018 Jul;32(7):1609-1620. doi: 10.1038/s41375-018-0035-y. Epub 2018 Feb 23.

46.

Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.

Schrader A, Crispatzu G, Oberbeck S, Mayer P, Pützer S, von Jan J, Vasyutina E, Warner K, Weit N, Pflug N, Braun T, Andersson EI, Yadav B, Riabinska A, Maurer B, Ventura Ferreira MS, Beier F, Altmüller J, Lanasa M, Herling CD, Haferlach T, Stilgenbauer S, Hopfinger G, Peifer M, Brümmendorf TH, Nürnberg P, Elenitoba-Johnson KSJ, Zha S, Hallek M, Moriggl R, Reinhardt HC, Stern MH, Mustjoki S, Newrzela S, Frommolt P, Herling M.

Nat Commun. 2018 Feb 15;9(1):697. doi: 10.1038/s41467-017-02688-6.

47.

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ.

Blood. 2018 Mar 22;131(12):1275-1291. doi: 10.1182/blood-2017-09-801498. Epub 2018 Jan 12. Review.

48.

Chromothripsis in acute myeloid leukemia: Biological features and impact on survival.

Fontana MC, Marconi G, Feenstra JDM, Fonzi E, Papayannidis C, di Rorá AGL, Padella A, Solli V, Franchini E, Ottaviani E, Ferrari A, Baldazzi C, Testoni N, Iacobucci I, Soverini S, Haferlach T, Guadagnuolo V, Semerad L, Doubek M, Steurer M, Racil Z, Paolini S, Manfrini M, Cavo M, Simonetti G, Kralovics R, Martinelli G.

Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.351. [Epub ahead of print]

49.

Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal.

Valent P, Akin C, Arock M, Bock C, George TI, Galli SJ, Gotlib J, Haferlach T, Hoermann G, Hermine O, Jäger U, Kenner L, Kreipe H, Majeti R, Metcalfe DD, Orfao A, Reiter A, Sperr WR, Staber PB, Sotlar K, Schiffer C, Superti-Furga G, Horny HP.

EBioMedicine. 2017 Dec;26:17-24. doi: 10.1016/j.ebiom.2017.11.024. Epub 2017 Nov 26. Review.

50.

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions.

Valent P, Orazi A, Steensma DP, Ebert BL, Haase D, Malcovati L, van de Loosdrecht AA, Haferlach T, Westers TM, Wells DA, Giagounidis A, Loken M, Orfao A, Lübbert M, Ganser A, Hofmann WK, Ogata K, Schanz J, Béné MC, Hoermann G, Sperr WR, Sotlar K, Bettelheim P, Stauder R, Pfeilstöcker M, Horny HP, Germing U, Greenberg P, Bennett JM.

Oncotarget. 2017 Jul 5;8(43):73483-73500. doi: 10.18632/oncotarget.19008. eCollection 2017 Sep 26.

Supplemental Content

Loading ...
Support Center